Terkko Navigator / -/ Feeds / " ( ( Muskariiniantagonistit )|( Muskariiniantagonisti )|( Muskariinivastavaikuttajat )|( M"

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists

Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia

Muscarinic Modulation of Synaptic Transmission via Endocannabinoid Signalling in the Rat Midbrain Periaqueductal Gray

Muscarinic M1, but not M4, receptor antagonism impairs divided attention in male rats

Muscarinic acetylcholine receptor M5 is involved in spermatogenesis through the modification of cell-cell junctions

Bis-Quinolinium Cyclophane Blockers of SK Potassium Channels Are Antagonists of M3 Muscarinic Acetylcholine Receptors.

Sub-type selective muscarinic acetylcholine receptor modulation for the treatment of parkinsonian tremor

Model-based prediction of muscarinic receptor function from auditory mismatch negativity responses

Cells, Vol. 10, Pages 1237: Effects of (a Combination of) the Beta2-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction

Potential Role for Combined Subtype-Selective Targeting of M₁ and M₃ Muscarinic Receptors in Gastrointestinal and Liver Diseases

BLOCKADE OF M4 MUSCARINIC RECEPTORS ON STRIATAL CHOLINERGIC INTERNEURONS NORMALIZES STRIATAL DOPAMINE RELEASE IN A MOUSE MODEL OF DYT1-TOR1A DYSTONIA

Intra-dorsal striatal acetylcholine M1 but not dopaminergic D1 or glutamatergic NMDA receptor antagonists inhibit the consolidation of duration memory in interval timing

Design, Synthesis, and Biological Evaluation of 4,4'-Difluorobenzhydrol Carbamates as Selective M₁ Antagonists

Muscarinic receptor antagonists and airway inflammation: a systematic review on pharmacological models

[ASAP] Discovery of the First Selective M₄ Muscarinic Acetylcholine Receptor Antagonists with <italic toggle="yes">in Vivo</italic> Antiparkinsonian and Antidystonic Efficacy

Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor

A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome

Implications of Antimuscarinic Autoantibodies in Postural Tachycardia Syndrome

IJMS, Vol. 22, Pages 12399: The Effectiveness in Activating M-Type K+ Current Produced by Solifenacin ([(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate): Independent of Its Antimuscarinic Action

Resource use and healthcare costs in patients with overactive bladder who initiate treatment with mirabegron or antimuscarinic monotherapy in Catalonia: the MIRACAT study

Pharmaceuticals, Vol. 13, Pages 437: Synthesis, Biological, and Computational Evaluation of Antagonistic, Chiral Hydrobenzoin Esters of Arecaidine Targeting mAChR M1

Short-acting inhaled bronchodilators for cystic fibrosis

Short-acting inhaled bronchodilators for cystic fibrosis

Short-acting inhaled bronchodilators for cystic fibrosis

Sensors, Vol. 22, Pages 2264: Use of a Wearable Biosensor to Study Heart Rate Variability in Chronic Obstructive Pulmonary Disease and Its Relationship to Disease Severity

The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making.

Mecamylamine inhibits seizure-like activity in CA1-CA3 hippocampus through antagonism to nicotinic receptors

Isolated airways in equine respiratory pharmacology: They never lie.

Current pharmacotherapy of overactive bladder

Pharmaceuticals, Vol. 14, Pages 1147: New Uncharged 2-Thienostilbene Oximes as Reactivators of Organophosphate-Inhibited Cholinesterases

Japanese guidelines for adult asthma 2020.

Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management

Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma

Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma

Social Isolation: How Can the Effects on the Cholinergic System Be Isolated?

Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis

Molecules, Vol. 27, Pages 3339: Safety Assessment and Pain Relief Properties of Saffron from Taliouine Region (Morocco)

Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines Guidelines of the Finnish Medical Society Duodecim and the Finnish Respiratory Society.

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study

Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study